<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714983</url>
  </required_header>
  <id_info>
    <org_study_id>2440LM-002</org_study_id>
    <nct_id>NCT04714983</nct_id>
  </id_info>
  <brief_title>DNX-2440 for Resectable Colorectal Liver Metastasis</brief_title>
  <official_title>A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DNAtrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DNAtrix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in&#xD;
      patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have&#xD;
      curative-intent liver resection surgery. Up to 18 patients will receive two sequential&#xD;
      intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver&#xD;
      resection, to evaluate safety and biological endpoints across 3 dose levels (dose&#xD;
      escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically&#xD;
      appropriate dose will be administered using the same schema for an additional 12 patients&#xD;
      with colorectal cancer liver metastasis (expansion cohort) using established biologic&#xD;
      endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) achieved during dose-escalation phase</measure>
    <time_frame>1.5 Years</time_frame>
    <description>The MTD will be defined as the highest tolerated dose below the dose that results in greater than or equal to one-third of the subjects exposed who experience a dose-limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of DNX-2440 assessed by Tumor Regression Grade (TRG) score</measure>
    <time_frame>3 Years</time_frame>
    <description>Efficacy in tumor cell killing will be measured using the TRG score (1-5) for the resected specimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral replication</measure>
    <time_frame>3 Years</time_frame>
    <description>Viral replication will be assessed by quantitative measurement of viral protein expression by IHC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Immune response with cell response panels</measure>
    <time_frame>3 Years</time_frame>
    <description>Immunotherapeutic responses will be assessed by examining features and measuring changes following the intervention for Immunologic microenvironment (T-cell and Myeloid-cell response panels-tissue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Immune response with ImmunoSEQsec</measure>
    <time_frame>3 Years</time_frame>
    <description>Immunotherapeutic responses will be assessed by measuring changes in T-cell receptor (TCR) repertoire - tissue and blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Immune response with ELISPOT</measure>
    <time_frame>3 Years</time_frame>
    <description>Immunotherapeutic responses will be assessed by measuring T-cell response (ELISPOT - tissue/blood).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Liver Metastasis Colon Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Periampullary Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Renal Cell Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Dose-level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose-level 1 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose-level 2 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose-level 3 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNX-2440</intervention_name>
    <description>DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.</description>
    <arm_group_label>Dose-level 1</arm_group_label>
    <arm_group_label>Dose-level 2</arm_group_label>
    <arm_group_label>Dose-level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged ≥ 18 years at time of consent&#xD;
&#xD;
          -  Diagnosis of liver metastases from colorectal, breast, gastric, periampullary,&#xD;
             melanoma, renal cell cancer, sarcoma, squamous cell carcinoma or gastrointestinal&#xD;
             stromal tumor&#xD;
&#xD;
          -  Multiple (≥ 2) liver tumors&#xD;
&#xD;
          -  Candidate for curative-intent surgery&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Candidates eligible for targeted therapy, as per standard of care guidelines (and&#xD;
             based on mutational status as indicated), must have completed therapy&#xD;
&#xD;
          -  Preoperative chemotherapy is allowed&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Recurrence of liver metastasis&#xD;
&#xD;
          -  Diagnosis of neuroendocrine tumor liver metastasis&#xD;
&#xD;
          -  Liver metastasis treated with &gt; 12 cycles of systemic chemotherapy&#xD;
&#xD;
          -  Condition that requires ongoing systemic immunosuppressive therapy&#xD;
&#xD;
          -  Evidence of inadequate organ function based on lab parameters&#xD;
&#xD;
          -  Liver transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase&#xD;
             [ALT]) or total bilirubin &gt; 5x the upper limits of normal&#xD;
&#xD;
          -  Males or females who refuse to use a double-barrier form of birth control during the&#xD;
             study and for up to 6 months after injection with DNX-2440&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Gady, BS</last_name>
    <role>Study Director</role>
    <affiliation>DNAtrix, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Gady, BS</last_name>
    <phone>832-930-2401</phone>
    <email>2440LM-002study@DNAtrix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Brelsford</last_name>
      <phone>813-745-3772</phone>
      <email>Marjorie.Brelsford@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Anaya, MD</last_name>
      <phone>813-745-1813</phone>
      <email>Daniel.AnayaSaenz@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Anaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

